View details of this raise on Seedstage

Lehi, UT

Advancing a novel immune-based cancer treatment that disguises cancer cells as viruses for precise targeting.

• Breakthrough approach: Uses AI to disguise cancer cells as known pathogens, prompting immune response.
• Pre-clinical validation: Early-stage tests have shown successful detection and targeting of cancer cells.
• Industry partnerships: Collaborating with leaders like Flashpoint Therapeutics and Cytiva.
• Experienced team: Led by scientists with track records in cancer drug development.
• High market demand: Positioned in a global cancer immunotherapy market expected to triple by 2031.

CancerVax is a pre-clinical biotechnology company developing a novel cancer treatment platform designed to harness the body’s immune system to detect and destroy cancer cells. Unlike traditional immunotherapies that attempt to teach the immune system to recognize cancer, CancerVax’s technology disguises cancer cells as known pathogens, such as measles, prompting the immune system to respond immediately. Their method integrates AI-powered detection and a dual-marker strategy to precisely target cancer cells while leaving healthy tissue unharmed. The platform has shown promising in-vitro results and is being developed in partnership with leading biotech collaborators.

The purpose of this fundraising round is to accelerate the development of CancerVax’s Universal Cancer Treatment Platform. Funds will support pre-clinical research, including animal testing, and help move the company toward clinical trials. Backed by a team of experienced scientists and advisors, CancerVax is working to establish a customizable, off-the-shelf cancer therapy. As the demand for more effective and less invasive treatments continues to grow, this technology has the potential to disrupt conventional oncology approaches. The goal is to deliver a targeted, safe, and efficient treatment option that could one day make managing cancer as simple as receiving a routine vaccine.

Company Info

CancerVax is a biotech company developing an AI-powered platform that disguises cancer cells to trigger targeted immune responses.

CancerVax is a pre-clinical biotechnology company developing a Universal Cancer Treatment Platform that aims to help the immune system recognize and eliminate cancer cells. Its proprietary technology uses artificial intelligence to detect cancer cells and then mark them by engineering them to display proteins associated with well-known pathogens such as measles. This process is intended to provoke a targeted immune response, leveraging the body’s existing defenses to attack the altered cancer cells.

The platform employs a nanoparticle delivery system and a two-step detection method to identify cancer cells with precision. CancerVax is collaborating with scientific partners including Flashpoint Therapeutics and Cytiva to advance its technology. The company has completed in-vitro validation and plans to initiate animal testing by 2026. Positioned within the growing cancer immunotherapy market, CancerVax differentiates itself by attempting to “trick” the immune system rather than teaching it new responses, offering a potentially more immediate and effective treatment for a wide range of cancers.